徐华娥，南京医科大学高层次引进人才、特聘教授、博导，南京医科大学药学院药剂学系主任，美国MD安德森癌症中心放射肿瘤学系高级访问学者，江苏省第六期“333高层次人才培养工程”第三层次培养对象。现任中国抗癌协会纳米肿瘤学分会专委会委员、江苏省中医药学会第十二届理事会理事、江苏省药学会医院药学专业委员会委员、江苏省药学会感染药学专业委员会常务委员、南京药学会药剂与药理专委会委员，国家自然科学基金优秀青年基金、面上项目及青年基金一审专家，Current Drug Delivery、AJPS等杂志编委，为本领域如AM、AFM等顶刊同行评议的审稿人。
长期围绕多功能智能纳米递药平台的构建及在重大疾病（如肿瘤、脑部疾病、免疫性疾病等）中的应用展开相关研究，主要研究方向：1、基于肿瘤、心脑血管等重大疾病的智能药物递送体系的开发及应用； 2、基因、疫苗等新型纳米药物递送体系的构建及应用；3、新型高端药物制剂的开发。作为项目负责人主持国家自然科学基金5项，以第一或通讯作者在 Adv Mater、Adv Funct Mater、Biomaterials、Chem Eng J 、Acta biomater、Anal Chem等权威期刊上发表论文40余篇。迄今为止，根据Google Scholar统计分析，文章总被引频次1971次，近5年被引频次1087次，单篇最高被引频次249次，H指数25。
曾指导研究生获得第十三届全国大学生药苑论坛创新成果二等奖，第二届生物磁学与磁性纳米材料学术会议暨第九届全国生物与医学纳米技术博士生学术论坛获优秀展报一等奖，第四届脑科学与药学前沿高峰论坛青年学者论文Poster比赛三等奖，发表多篇高水平论文，毕业去向良好，多选择继续深造或进入各大高校、医院、药企等单位工作。
招生方向：
1.新型药物、基因、疫苗递送系统研究与开发
2.新型生物材料的医药学应用
3.药学、药剂学专业
联系方式：
代表性论文：
1.Zhang F, Yang N, Zhou F, Qiao R, Wan Y, Liu R, Yang S, Gu M, Xu H*, Dong X*, Wang G*. (2024). Orthogonally sequential activation of self‐powered DNAzymes cascade for reliable monitoring of mRNA in living cells. Advanced Healthc Mater, 2024, 2303074.
2.Wu T#, Lang T#, Zheng C, Yan W, Li Y, Zhu R, Huang X, Xu H*, Li Y*, Yin Q*. Promote intratumoral drug release and penetration to counteract docetaxel-induced metastasis by photosensitizer-modified red blood cell membrane-coated nanoparticle. Adv Funct Mater, 2023, 33: 2212109.
3.Xu Y, Wei Z, Yang W, Guo Y, Shao J, Si W*, Xu H*, Wang W, Dong X*. H2O2 responsive CO gas release platform with CA IX-Targeting for inhibiting tumor growth and metastasis. Chem Eng J, 2023, 463: 142371.
4.Yin J, Wang C, Zhao L, Xu K, Guo Y, Song X*, Shao J, Xu H*, Dong X*. Acidity-responsive nanoplatforms aggravate tumor hypoxia via multiple pathways for amplified chemotherapy. Biomaterials, 2023, 296: 122094.
5.Wang X, Zhao L, Wang C, Wang L, Wu H, Song X*, Wang W, Xu H*, Dong X*. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib. Acta biomater, 2023, 159, 237-246.
6.Sun S#, Gu W#, Wu H#, Zhao Q#, Qian S, Xiao H, Yang K, Liu J, Jin Y, Hu C, Gao Y, Xu H*, Liu H*, Ji J*, Chen Y*. Immunostimulant in situ hydrogel improves synergetic radioimmunotherapy of malignant glioblastoma relapse post-resection. Adv Funct Mater, 2022, 32: 2205038.
7.Wang J#, Wu H#, Zhao Q#, Zou Y, Ding D, Yin H*, Xu H*. Aggregation-induced emission photosensitizer synergizes photodynamic therapy and the inhibition of the NF-κB signaling pathway to overcome hypoxia in breast cancer. ACS Appl Mater Interfaces, 2022, 14: 29613-29625.
8.Yao Y#, Zhang Y#, Zhang J, Yang X, Ding D, Shi Y*, Xu H*, Gao X*. Azulene-containing squaraines for photoacoustic imaging and photothermal therapy. ACS Appl Mater Interfaces, 2022, 14: 19192-19203.
9.Wang T#, Wang J#, Jiang H#, Ni M, Zou Y, Chen Y, Wu T, Ding D, Xu H*, Li X*. Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments. Mater Today Bio, 2022, 15: 100304.
10.Zhang Z#, Ji Y#, Hu N#, Yu Q, Zhang X, Li J, Wu F*, Xu H*, Tang Q*, Li X*. Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal cancer treatment. Asian J Pharm Sci, 2022, 17: 751-766.
11.Zhang M, Wang C, Yang C, Wu H, Xu H*, Liang G*. Using fluorescence on/off to trace tandem nanofiber assembly/disassembly in living cells. Anal Chem, 2021, 93: 5665-5669.
12.Li X#, Yu N#, Li J, Bai J, Ding D, Tang Q*, Xu H*. Novel “carrier-free” nanofiber codelivery systems with the synergistic antitumor effect of paclitaxel and tetrandrine through the enhancement of mitochondrial apoptosis. ACS Appl Mater Interfaces, 2020, 12: 10096-10106.
13.Xu H#, Wang T#, Yang C, Li X*, Liu G, Singh PK, Krishnan S*, Ding D*. Supramolecular nanofibers of curcumin for highly amplified radiosensitization of colorectal cancers to ionizing radiation. Adv Funct Mater, 2018, 28: 1707140.
14.Yu CY#, Xu H#, Ji S, Kwok RT, Lam JW, Li X*, Krishnan S, Ding D*, Tang BZ*. Mitochondrion-anchoring photosensitizer with aggregation-induced emission characteristics synergistically boosts the radiosensitivity of cancer cells to ionizing radiation. Adv Mater, 2017, 29: 1606167.
